Economic analysis of prostate-specific antigen screening and selective treatment strategies

JAMA Oncology

Volumn 2, Issue 7, 2016, Pages 890-899

  Roth, Joshua A ^a,b   Gulati, Roman ^a   Gore, John L ^c   Cooperberg, Matthew R ^d   Etzioni, Ruth ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; BIOPSY; BLOOD; CANCER GRADING; CANCER STAGING; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE TUMOR; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

ADULT; BIOPSY; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 85010653069     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.6275     Document Type: Article

References (55)

1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
2. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426.
3. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158 (10):761-769.
4. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol. 2012;30 (24):3020-3025.
5. Andriole GL, Crawford ED, Grubb RL III, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-132.
6. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
7. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959): 2027-2035.
8. Chou R, LeFevreML. Prostate cancer screening: the evidence, the recommendations, and the clinical implications. JAMA. 2011;306(24):2721-2722.
9. Welch HG. A piece ofmy mind: making the call. JAMA. 2011;306(24):2649-2650.
10. Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol. 2011;64(12):1412-1417.
11. Loeb S, Vonesh EF,Metter EJ, Carter HB, Gann PH, CatalonaWJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011; 29(4):464-467.
12. Heijnsdijk EA,Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595-605.
13. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening. Med Care. 2013;51(4):295-300.
14. Gulati R, Tsodikov A, Etzioni R, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014; 120(22):3519-3526.
15. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
16. Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force review. J Clin Oncol. 2012;30 (21):2581-2584.
17. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.
18. Wilt TJ, Harris RP, Qaseem A; High Value Care Task Force of the American College of Physicians. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718-725.
19. Ganz PA, Barry JM, BurkeW, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156(8):591-595.
20. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR,Miller DC; Michigan Urological Surgery Improvement Collaborative. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015;67(1): 44-50.
21. CooperbergMR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.
22. Gulati R, Inoue L, Katcher J, HazeltonW, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010; 11(4):707-719.
23. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181.
24. Carroll PR, Parsons JK, Andriole G, et al; National Comprehensive Cancer Network. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211-1219.
25. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
26. CooperbergMR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7): 1117-1123.
27. Bill-Axelson A, Holmberg L, RuutuM, et al; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
28. CooperbergMR, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437-450.
29. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13): 2883-2891.
30. Gulati R, Tsodikov A,Wever EM, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control. 2012;23(6):827-835.
31. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
32. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43(4):347-355.
33. Centers for Medicare & Medicaid Services. HCPCS general information. https://www.cms.gov /Medicare/Coding/MedHCPCSGenInfo/index .html?redirect=/MedHCPCSGenInfo/. Modified December 20, 2015. Accessed August 23, 2014.
34. Wang SY,Wang R, Yu JB, et al. Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. Med Care. 2014;52(8):680-687.
35. Hayes JH, Ollendorf DA, Pearson SD, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013; 158(12):853-860.
36. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373-2380.
37. Mobley LR, Hoerger TJ,Wittenborn JS, Galuska DA, Rao JK. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006;26(2):194-206.
38. GoldM, Siegel J, Russell L,Weinstein M. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
39. O'Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics. 2005;23 (6):529-536.
40. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
41. Berry SR, Bell CM, Ubel PA, et al. Continental divide? the attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28(27):4149-4153.
42. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood). 2010;29(1):196-202.
43. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? a systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82-88.
44. Neumann PJ, Cohen JT,Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.
45. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12(1):20-27.
46. Myers EMA, Lan S, Posey RE, Gray R, Sanders GD. Value-of-Information Analysis for Patient-Centered Outcomes Research Prioritization. Washington, DC: Patient-Centered Outcomes Research Institute; 2012.
47. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
48. Garg V, Gu NY, Borrego ME, Raisch DW. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):327-342.
49. Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA. Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making. 2012;32(2):337-349.
50. Heijnsdijk EA, de Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst. 2015;107(1):366.
51. Gulati R,Wever EM, Tsodikov A, et al. What if I don't treatmy PSA-detected prostate cancer? answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011;20(5):740-750.
52. Wever EM, Draisma G, Heijnsdijk EA, et al. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst. 2010;102(5):352-355.
53. Sox HC. Quality of life and guidelines for PSA screening. N Engl J Med. 2012;367(7):669-671.
54. Vickers A, Carlsson S, Laudone V, Lilja H. It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening. Eur Urol. 2014;66(2):188-190.
55. Murphy DG, Loeb S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat Rev Urol. 2015;12(11):604-605.